Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual (Q35182925)

7 August 2017

1 reference

title

Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual (English)

1 reference

7 August 2017

1 reference

13

Monica Morrow

1 reference

7 August 2017

18

Donald L Weaver

1 reference

7 August 2017

20

Frederick L Greene

1 reference

7 August 2017

12

Robert V P Hutter

1 reference

7 August 2017

1

S Eva Singletary

1 reference

7 August 2017

Craig Allred

2

1 reference

7 August 2017

Pandora Ashley

3

1 reference

7 August 2017

Lawrence W Bassett

4

1 reference

7 August 2017

Donald Berry

5

1 reference

7 August 2017

Kirby I Bland

6

1 reference

7 August 2017

Patrick I Borgen

7

1 reference

7 August 2017

Gary M Clark

8

1 reference

7 August 2017

Stephen B Edge

9

1 reference

7 August 2017

Daniel F Hayes

10

1 reference

7 August 2017

Lorie L Hughes

11

1 reference

7 August 2017

David L Page

14

1 reference

7 August 2017

Abram Recht

15

1 reference

7 August 2017

Richard L Theriault

16

1 reference

7 August 2017

Ann Thor

17

1 reference

7 August 2017

H Samuel Wieand

19

1 reference

7 August 2017

1 August 2003

1 reference

Surgical Clinics of North America

7 August 2017

1 reference

7 August 2017

83

1 reference

7 August 2017

4

1 reference

7 August 2017

803-819

1 reference

The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Systemic treatment after sentinel lymph node biopsy in breast cancer: who, what, and why?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

American Joint Committee on Cancer prognostic factors consensus conference

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Significance of Axillary Macrometastases and Micrometastases in Mammary Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Prognostic significance of occult lymph node metastases in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Detection and significance of occult metastases in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Detection of micrometastases in lymph nodes from patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Detection of micrometastasis in the sentinel lymph nodes in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Looking forward in diagnostic pathology: the molecular superhighway

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Significance of axillary lymph node metastasis in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Management and survival of female breast cancer: results of a national survey by the American College of Surgeons

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Comprehensive review of the management of internal mammary lymph node metastases in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

I. The Results of Radical Operations for the Cure of Carcinoma of the Breast

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

The significance of a supraclavicular node metastasis in patients with breast cancer. A literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

The prognosis of small primary breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0).

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192).

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900034-3

7 January 2021

10.1016/S0039-6109(03)00034-3

Identifiers

DOI

1 reference

7 August 2017

1 reference